iCAD Showcases New ProFound Cloud, Enhanced ProFound Detection Workstation Features and New Strategic Partnerships at SBI Annual Symposium
April 11, 2024 — iCAD, Inc., a global leader in clinically proven AI-powered cancer detection solutions, announced today it will showcase its ProFound Breast Health Suite of AI solutions, including the newly released ProFound Cloud, powered by Google Cloud and Google Health AI architecture, while also highlighting its recently announced partnership with Densitas, a global leader in AI solutions for breast cancer screening, at the Society for Breast Imaging (SBI) annual symposium, April 11-14 in Montreal, Canada. In addition, iCAD will feature its recent release of the ProFound Detection Workstation features for streamlined mammogram interpretations in booth #512.
“We’re excited to highlight our recent notable advancements at the SBI annual symposium this year,” said Dana Brown, President and CEO of iCAD. “With the recent introduction of the ProFound Cloud, powered by Google’s innovative technology, we’re ensuring that critical insights are readily accessible to empower radiologists in the early detection of breast cancer.
“Our partnership with Densitas, who provides mammography facilities with actionable, evidence-based intelligence to capture quality images, combined with iCAD’s ProFound Breast Health Suite that points radiologists toward prioritized areas of concern on mammograms,” continued Brown, “patients are the ultimate beneficiaries of our combined suite of offerings which facilitate more holistic breast health solutions. Together with ProFound Cloud and our latest ProFound Detection workstation update, clinicians are empowered with faster, more accurate ways to pinpoint areas of concern and enhance patient outcomes.”
SBI attendees can also view a demonstration of ProFound Cloud, a secure method of transporting and processing mammography screening data between imaging sources. ProFound Cloud, which runs on Google Cloud and Google Health AI architecture, allows for processed data to be seamlessly delivered to systems that utilize AI outputs, including mammography review workstations, PACS, and image and data storage systems.
Visitors to the iCAD booth will also be able to witness the new advanced workstation features for ProFound Detection for both 2D and 3D mammography in its latest V3 Service Pack update. Designed to enhance the readability of iCAD results by limiting lesion marks to three per image and color-coding key findings on workstation displays, this update ensures that radiologists are directed toward the most critical information based on level of suspicion, thus heightening the efficiency of the screening process.
The company also recently announced a philanthropic partnership with RAD-AID International to implement ProFound AI Detection in low-resource medical institutions in underserved regions of the world. The first-of-its-kind mammography AI-based decision support program will commence in Guyana using iCAD’s ProFound Detection to increase and improve breast cancer detection for patients in need, in aim of reducing health care disparities and increasing health equity by widening access to earlier cancer diagnostics.
Symposium attendees are invited to visit iCAD’s booth #512 or schedule a meeting at https://www.icadmed.com/about/news-events/upcoming-tradeshows-and-meetings/sbi-2024 to discuss iCAD’s newest partnerships and product demonstrations.
For more information: www.icadmed.com
